Last Price$12.92Cboe Real-Time Last Sale as of 11:50AM ET 8/08/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.14(1.07%)
Bid (Size)$12.94 (100)
Ask (Size)$13.02 (400)
Day Low / High$12.92 - 13.50
Volume165.4 K

View Biotechnology IndustryPeer Comparison as of 08/08/2022


Alector Inc ( NASDAQ )

Price: $12.92
Change: -0.14 (1.07%)
Volume: 165.4 K
11:50AM ET 8/08/2022

Sorrento Therapeutics Inc ( NASDAQ )

Price: $2.74
Change: -0.02 (0.72%)
Volume: 3.4 M
11:51AM ET 8/08/2022

Cogent Biosciences Inc ( NASDAQ )

Price: $12.33
Change: +0.28 (2.32%)
Volume: 504.8 K
11:49AM ET 8/08/2022

Deciphera Pharmaceuticals Inc ( NASDAQ )

Price: $16.47
Change: -0.04 (0.24%)
Volume: 270.0 K
11:51AM ET 8/08/2022

Kura Oncology Inc ( NASDAQ )

Price: $15.50
Change: +0.01 (0.06%)
Volume: 267.0 K
11:49AM ET 8/08/2022

Read more news Recent News

Citigroup Adjusts Alector's Price Target to $19 From $34, Reiterates Buy Rating
7:41AM ET 7/11/2022 MT Newswires

Alector (ALEC) has an average rating of outperform and price targets ranging from $6 to $54, according to analysts polled by Capital IQ. (MT Newswires...

Alector Says Partner AbbVie Ends One of Two Programs in Alzheimer's Disease Collaboration
5:10AM ET 7/08/2022 MT Newswires

Alector (ALEC) said AbbVie (ABBV) subsidiary AbbVie Biotechnology ended one of the two programs in their 2017 Alzheimer's disease collaboration, according...

--Mizuho Securities Initiates Alector at Buy with $15 Price Target
10:26AM ET 7/07/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Mizuho Initiates Alector with Buy Rating, $15 Price Target, Represents 'Classic' Risk/Reward in Biotech
4:16PM ET 7/06/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionAlector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA. View company web site for more details
Address131 Oyster Point Boulevard
South San Francisco, California 94080-2029
Number of EmployeesN/A
Recent SEC Filing08/04/20228-K
Chief Executive Officer & DirectorArnon Rosenthal
President, Head-Research & DevelopmentSaraswati Kenkare-Mitra
Chief Financial, Accounting & Business OfficerMarc Edward Grasso
VP-Technology & Digital HealthCharles Wolfus

Company Highlights

Price Open$13.17
Previous Close$13.06
52 Week Range$7.50 - 29.30
Market Capitalization$1.1 B
Shares Outstanding83.3 M
SectorHealth Technology
Next Earnings Announcement11/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings33.49
Earnings per Share$0.38
Beta vs. S&P 500N/A
Revenue$27.7 M
Net Profit Margin12.06%
Return on Equity12.16%

Analyst Ratings as of 07/05/2022

Consensus RecommendationConsensus Icon
Powered by Factset